Biolight Life Sciences Ltd. (BOLT)

Overview

BioLight Life Sciences Ltd. is a pioneering force in the realm of ophthalmology, concentrated on the innovation, development, and marketing of a diverse range of products and product candidates designed to tackle various ophthalmic conditions. Originating as Bio Light Israeli Life Sciences Investments Ltd., the company underwent a name change in February 2016 to better reflect its specialized focus. Established in 2005 and headquartered in Tel Aviv, Israel, BioLight Life Sciences Ltd. leverages cutting-edge technology to address eye health issues with a primary aim at enhancing the quality of life for patients worldwide.

Products and Services

• DiagnosTear's TeaRx technology:
  

  A diagnostic platform, TeaRx stands out for its innovative approach to diagnosing diseases affecting the frontal areas of the eye. This technology analyzes various substances in teardrop compositions, enabling precise disease identification.

• ViSci's Eye D technology:
  

  Targeting glaucoma treatment, Eye D technology utilizes a subconjunctival implant to administer treatment directly, offering a novel approach to managing this condition.

• OphRx:
  

  A development segment specializing in creating drugs for the treatment of eye diseases, OphRx represents the company’s commitment to expanding its therapeutic offerings.

• Peripherex:
  

  This innovation focuses on the at-home and in-office diagnosis and monitoring of peripheral vision impairment. It is designed for use by eye care professionals and other providers to diagnose and monitor glaucoma and other diseases efficiently.

• AEYE:
  

  AEYE is dedicated to the development of artificial intelligence solutions tailored for various retinal diseases, embodying the intersection of AI and healthcare to deliver advanced diagnostic and treatment options.

• Tarsier:
  

  Utilizing its technological platform, Tarsier is working on TRS 01 for the treatment of Uveitis in patients experiencing high Intraocular Pressure (IPO), highlighting the company's focus on addressing specific and severe eye conditions.

• Belkin Vision:
  

  Belkin Vision is at the forefront of developing a fast and automatic laser device intended to provide glaucoma patients with short and effective treatments to lower Intraocular Pressure (IOP), innovating in glaucoma care.

• Sanoculis:
  

  With an emphasis on surgical innovation, Sanoculis is developing a new procedure aimed at treating Glaucoma. This approach represents a potentially groundbreaking advancement in the surgical management of the condition.